Calyxt, Inc. (CLXT)
$6.3
+0.33 (+5.53%)
Rating:
Recommendation:
Buy
| Symbol | CLXT |
|---|---|
| Price | $6.3 |
| Beta | 2.043 |
| Volume Avg. | 0.02M |
| Market Cap | 31.334M |
| Shares () | - |
| 52 Week Range | 6.01-38.85 |
| 1y Target Est | - |
| DCF Unlevered | CLXT DCF -> | |
|---|---|---|
| DCF Levered | CLXT LDCF -> | |
| ROE | -150.26% | Strong Sell |
| ROA | -60.19% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 537.76% | Strong Buy |
| P/E | -1.64 | Sell |
| P/B | 11.67 | Strong Buy |
Latest CLXT news
About
Download (Excel)Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.